Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/6/2025

LDL Cholesterol Goals for Patients with Hypertension

Risk Stratification for Determining LDL Goals

  • The European Society of Cardiology recommends that for hypertensive patients at low or moderate cardiovascular risk, the LDL cholesterol target is <5 mmol/L (<190 mg/dL) for total cholesterol and <3 mmol/L (<115 mg/dL) for LDL cholesterol 1
  • For hypertensive patients at high cardiovascular risk, an LDL cholesterol goal of <2.5 mmol/L (<100 mg/dL) is recommended by the European Society of Cardiology 1
  • High-risk status is typically defined by the presence of multiple risk factors, target organ damage, or diabetes without end-organ damage, according to the American College of Cardiology and the American Heart Association 3, 4
  • When LDL-lowering therapy is employed in high-risk patients, the intensity should be sufficient to achieve at least a 30-40% reduction in LDL-C levels, as recommended by the American Heart Association 5

Factors Defining "Very High Risk" Status in Hypertensive Patients

  • Established cardiovascular disease, severe chronic kidney disease, or diabetes with target organ damage are factors that define very high-risk status in hypertensive patients, according to the European Society of Cardiology 1, 2
  • Multiple major risk factors, especially poorly controlled hypertension, are also factors that define very high-risk status in hypertensive patients, as stated by the American Heart Association 4

Treatment Approach to Achieve LDL Goals

  • The European Society of Cardiology recommends that statin therapy should be initiated for hypertensive patients at high or very high cardiovascular risk 1
  • Therapeutic lifestyle changes remain an essential modality in clinical management for all hypertensive patients regardless of LDL-C level, according to the American Heart Association 5

Clinical Benefits of Achieving LDL Goals

  • Clinical trials have demonstrated significant reductions in cardiovascular events with statin therapy in high-risk patients, as reported by the American College of Cardiology 3, 7
  • Evidence suggests that additional benefit may be obtained by reducing LDL-C to substantially below 100 mg/dL, with no apparent threshold below which no further benefit is achieved, according to the American Heart Association 4, 5